Welcome to the Pharmacokinetics Research Group
Pharmacokinetics is the quantitative assessment of what the body does to a chemical following exposure. The fate of a chemical in a living organism is a function of its physical-chemical properties as well as the anatomy and physiology of the organism. Four main concepts form the basis for describing the rate and extent of exposure. These are Absorption, Distribution, Metabolism and Excretion, or ADME for short.
Our research is focused on building virtual organisms to study the pharmacokinetics of drugs and environmental contaminants. Physiologically-based pharmacokinetic (PBPK) models provide a mechanistic means of understanding how changes in anatomy and physiology can affect the ADME of a chemical. PBPK models are predictive and can be used to scale pharmacokinetics across species (e.g., rat to human) and within a species (e.g., healthy adult humans to children or patients) with an eye towards determining the right dose (in medicine) or determining differential risks associated with contaminant exposure (in human health risk assessment).
This website will provide you with further details of our current and future pharmacokinetic research. Peruse the list of publications and courses that I teach and email me if you have questions about the research or the website.
Students interested in graduate studies at either the M.Sc. or Ph.D. level with interests or experience in the following areas:
- PBPK modeling
- Pediatric PBPK modeling
- PK/PD modeling
can e-mail me directly: firstname.lastname@example.org
I am particularly interested in students who possess strong mathematical and/or statistical skills.
- Oct. 16, 2018
The Grand Challenges 2018 Annual Meeting (Oct 15-18, 2018) featured a panel on PBPK modeling and simulation in advancing drug development in global health. Dr. Edginton was invited by the Bill & Melinda Gates Foundation to participate along with:
- Oct. 15, 2018
Andrea Edginton PhD, Michael Neely, MD (University of Southern California) and Joerg Lippert PhD (Bayer, Germany) receive a US FDA grant ($900,000 US 2018-2021) on PBPK and Population Modeling Seamlessly Linked to Clinical Trial Simulation in an Open-Source Software Platform.
- Oct. 15, 2018
Congratulations to Paul Malik for receiving a three year CIHR Doctoral Scholarship ($105,000 over three years). The tenure of the award is 2018-2021.